Abstract

Synthetic Lethality (SL) is currently defined as a type of genetic interaction in which the loss of function of either of two genes individually has limited effect in cell viability but inactivation of both genes simultaneously leads to cell death. Given the profound genomic aberrations acquired by tumor cells, which can be systematically identified with -omics data, SL is a promising concept in cancer research. In particular, SL has received much attention in the area of cancer metabolism, due to the fact that relevant functional alterations concentrate on key metabolic pathways that promote cellular proliferation. With the extensive prior knowledge about human metabolic networks, a number of computational methods have been developed to predict SL in cancer metabolism, including the genetic Minimal Cut Sets (gMCSs) approach. A major challenge in the application of SL approaches to cancer metabolism is to systematically integrate tumor microenvironment, given that genetic interactions and nutritional availability are interconnected to support proliferation. Here, we propose a more general definition of SL for cancer metabolism that combines genetic and environmental interactions, namely loss of gene functions and absence of nutrients in the environment. We extend our gMCSs approach to determine this new family of metabolic synthetic lethal interactions. A computational and experimental proof-of-concept is presented for predicting the lethality of dihydrofolate reductase (DHFR) inhibition in different environments. Finally, our approach is applied to identify extracellular nutrient dependences of tumor cells, elucidating cholesterol and myo-inositol depletion as potential vulnerabilities in different malignancies.

Highlights

  • The main challenge of precision oncology is to be able to translate accumulating–omics data into actionable treatments, personalized for individual patients [1]

  • We previously developed a computational framework to predict synthetic lethality in cancer metabolism based on the concept of genetic Minimal Cut Sets [14]

  • In the light of the above definition, we extend the genetic Minimal Cut Sets (gMCSs) approach to search for this family of synthetic lethal interactions

Read more

Summary

Introduction

The main challenge of precision oncology is to be able to translate accumulating–omics data into actionable treatments, personalized for individual patients [1]. Given the underlying genetic variations in tumor cells, SL largely expands the number of possible drug targets and creates an opportunity for more selective therapies [3]. Extensive work has been done to predict SL in cancer using both experimental and computational approaches [4–7]. These approaches have been mainly driven by the availability of large-scale gene knockout screening data for an increasing number of cancer cell lines [8,9]. They provide an experimental in vitro measure of cancer gene essentiality, which can be integrated with genomic and transcriptomic data in order to hypothesize SL and identify response biomarkers

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call